Phibro Animal Health (NASDAQ:PAHC) Upgraded to Hold at BNP Paribas

Phibro Animal Health (NASDAQ:PAHC) was upgraded by research analysts at BNP Paribas to a “hold” rating in a report released on Monday,Zacks.com reports.

PAHC has been the topic of several other research reports. BNP Paribas Exane upgraded shares of Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 target price on the stock in a research note on Monday. Morgan Stanley lifted their price target on shares of Phibro Animal Health from $20.00 to $21.00 and gave the company an “equal weight” rating in a report on Thursday, May 8th. Finally, Wall Street Zen raised shares of Phibro Animal Health from a “hold” rating to a “buy” rating in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $20.80.

Phibro Animal Health Trading Down 1.1%

Shares of Phibro Animal Health stock opened at $24.45 on Monday. The company has a market cap of $990.96 million, a price-to-earnings ratio of 31.35, a PEG ratio of 0.47 and a beta of 0.74. Phibro Animal Health has a 1 year low of $16.16 and a 1 year high of $26.55. The company’s fifty day simple moving average is $21.39 and its 200-day simple moving average is $21.89. The company has a current ratio of 2.91, a quick ratio of 1.23 and a debt-to-equity ratio of 2.67.

Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.52 by $0.11. Phibro Animal Health had a net margin of 2.68% and a return on equity of 30.51%. The company had revenue of $347.80 million during the quarter, compared to the consensus estimate of $352.41 million. As a group, sell-side analysts expect that Phibro Animal Health will post 1.95 EPS for the current year.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. bought a new position in Phibro Animal Health in the fourth quarter valued at about $29,000. National Bank of Canada FI acquired a new position in Phibro Animal Health during the 1st quarter valued at about $30,000. Lazard Asset Management LLC boosted its stake in shares of Phibro Animal Health by 2,739.7% in the 4th quarter. Lazard Asset Management LLC now owns 1,647 shares of the company’s stock valued at $34,000 after purchasing an additional 1,589 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Phibro Animal Health during the 4th quarter worth approximately $69,000. Finally, Virtus Fund Advisers LLC bought a new stake in shares of Phibro Animal Health during the fourth quarter worth approximately $69,000. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.